In conclusion, our somatic mutation profiling of the MAPK and PI3K pathway revealed alternative, low frequency mutations in the PI3K pathway that account for melanoma progression, and offer possible explanations for why targeted BRAFV600 inhibitors are not completely effective in treating metastatic melanoma patients. This evidence concerns the gene PIK3CA and metastatic melanoma.